Research

Steady progress: Review article on autoimmune encephalitis and how field is evolving July 31, 2017

As difficult as diagnosis and treatment are for autoimmune encephalitis, fortunately for the community of patients, families, and caregivers, rapid progress has been made within only a decade. A group of physicians in Oxford, England has published a review for the journal Neuropharmacology that summarizes the various types of AE, including a classification of syndromes, […]

British psychiatrists propose a change in practice August 25, 2018

Due to the nature of early symptoms in AE, studies have shown that patients often present first to psychiatrists or mental health facilities. Screening for the potential of autoimmune encephalitis may or may not be done, depending on awareness of the treating physicians and availability of testing. Drs. Pollack and Lennox of the UK have […]

Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders November 30, 2012

Dale et al Brain. 2012 Nov;135(Pt11):3453-68. https://academic.oup.com/brain/article/135/11/3453/272463 Recent reports of autoantibodies that bind to neuronal surface receptors or synaptic proteins have defined treatable forms of autoimmune encephalitis. Despite these developments, many cases of encephalitis remain unexplained. We have previously described a basal ganglia encephalitis with dominant movement and psychiatric disease, and proposed an autoimmune aetiology. […]

Evaluation of seizure treatment in AE April 15, 2020

In this nationwide cohort study, by De Bruijn and colleagues, the authors evaluated the seizure responses to immunotherapy and anti-epileptic drugs (AED’s) in patients with NMDAR, LGI1, and GABAbR encephalitis. The study included 153 patients with AE (53 LGI1, 75 NMDAR, 25 GABABR). Of those, 110 patients had epileptic seizures and were included in the […]

Association of Rituximab Use With Adverse Events February 24, 2021

A study done at Texas Children’s Hospital looked at the use of Rituximab for young people and its short- or long-term adverse events, infections, or recovery time of B lymphocyte subset counts and immunoglobulin levels. The study led by Dr. McAtee involved patients younger than 21 years receiving Rituximab for more than 25 indications, including […]

The emerging link between autoimmune disorders and neuropsychiatric disease. February 27, 2021

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086677/

Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures February 27, 2021

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592539/